{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T11:09:22Z","timestamp":1782299362745,"version":"3.54.5"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T00:00:00Z","timestamp":1704412800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T00:00:00Z","timestamp":1704412800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100019592","name":"Veterans Administration Medical Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019592","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Patients with chronic kidney disease (CKD) are at increased risk for multiple adverse events, several of which have been proven to be less likely with the use of sodium-glucose cotransporter-2 inhibitors (SGLT2i). As a result, guidelines now recommend SGLT2i be given to those with mild to moderate CKD and type 2 diabetes. The objective of this study is to evaluate if a pharmacist-driven SGLT2i prescribing initiative among eligible patients with CKD and diabetes within the VA could more rapidly improve the adoption of SGLT2i via a pragmatic approach aligned with learning health systems.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Eligible patients will be identified through an established VA diabetes dashboard. Veterans with an odd social security number (SSN), which is effectively a random number, will be the intervention group. Those with even SSNs will serve as the control while awaiting a second iteration of the same interventional program. The intervention will be implemented in a rolling fashion across one Veterans Integrated Service Network. Our primary outcome is initiation of an SGLT2i. Secondary outcomes will include medication adherence and safety-related outcomes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>This project tests the impact of a pharmacist-driven medication outreach initiative as a strategy to accelerate initiation of SGLT2i. The results of this work will not only illustrate the effectiveness of this strategy for SGLT2is but may also have implications for increasing other guideline-concordant care. Furthermore, the utilization of SSNs to select Veterans for the first wave of this program has created a pseudo-randomized interventional trial supporting a pragmatic learning health system approach.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>ISRCTN12374636.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12882-023-03446-1","type":"journal-article","created":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T16:02:53Z","timestamp":1704470573000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Pharmacist-driven outreach initiative to increase prescribing of sodium-glucose cotransporter-2 inhibitors in eligible VHA patients with chronic kidney disease: a study protocol"],"prefix":"10.1186","volume":"25","author":[{"given":"Deborah L.","family":"Pestka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pearl","family":"Huynh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica A.","family":"Rechtzigel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shari","family":"Kjos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa Marie","family":"Ellich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam N.","family":"Kaplan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brent C.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Atwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth A.","family":"Polsfuss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph Y.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Areef","family":"Ishani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,5]]},"reference":[{"key":"3446_CR1","unstructured":"2021. Chronic Kidney Disease in the United States, Published, August. 2, 2022. Accessed January 20, 2023. https:\/\/www.cdc.gov\/kidneydisease\/publications-resources\/ckd-national-facts.html."},{"issue":"3","key":"3446_CR2","doi-asserted-by":"publisher","first-page":"99","DOI":"10.12860\/jnp.2014.19","volume":"3","author":"S Said","year":"2014","unstructured":"Said S, Hernandez GT. The link between chronic Kidney Disease and Cardiovascular Disease. J Nephropathol. 2014;3(3):99\u2013104. https:\/\/doi.org\/10.12860\/jnp.2014.19.","journal-title":"J Nephropathol"},{"issue":"11","key":"3446_CR3","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1161\/CIRCULATIONAHA.120.050686","volume":"143","author":"J Jankowski","year":"2021","unstructured":"Jankowski J, Floege J, Fliser D, B\u00f6hm M, Marx N. Cardiovascular Disease in chronic Kidney Disease: pathophysiological insights and therapeutic options. Circulation. 2021;143(11):1157\u201372. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.050686.","journal-title":"Circulation"},{"issue":"2","key":"3446_CR4","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","volume":"388","author":"Empagliflozin in Patients with Chronic Kidney Disease","year":"2023","unstructured":"Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2023;388(2):117\u201327. https:\/\/doi.org\/10.1056\/NEJMoa2204233.","journal-title":"N Engl J Med"},{"issue":"22","key":"3446_CR5","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular outcomes, and mortality in type 2 Diabetes. N Engl J Med. 2015;373(22):2117\u201328. https:\/\/doi.org\/10.1056\/NEJMoa1504720.","journal-title":"N Engl J Med"},{"issue":"7","key":"3446_CR6","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and Cardiovascular and renal events in type 2 Diabetes. N Engl J Med. 2017;377(7):644\u201357. https:\/\/doi.org\/10.1056\/NEJMoa1611925.","journal-title":"N Engl J Med"},{"issue":"16","key":"3446_CR7","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G, et al. Empagliflozin in Heart Failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451\u201361. https:\/\/doi.org\/10.1056\/NEJMoa2107038.","journal-title":"N Engl J Med"},{"issue":"21","key":"3446_CR8","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with Heart Failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995\u20132008. https:\/\/doi.org\/10.1056\/NEJMoa1911303.","journal-title":"N Engl J Med"},{"issue":"4","key":"3446_CR9","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and Cardiovascular outcomes in type 2 Diabetes. N Engl J Med. 2019;380(4):347\u201357. https:\/\/doi.org\/10.1056\/NEJMoa1812389.","journal-title":"N Engl J Med"},{"issue":"24","key":"3446_CR10","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 Diabetes and Nephropathy. N Engl J Med. 2019;380(24):2295\u2013306. https:\/\/doi.org\/10.1056\/NEJMoa1811744.","journal-title":"N Engl J Med"},{"issue":"15","key":"3446_CR11","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic Kidney Disease. N Engl J Med. 2020;383(15):1436\u201346. https:\/\/doi.org\/10.1056\/NEJMoa2024816.","journal-title":"N Engl J Med"},{"issue":"Supplement1","key":"3446_CR12","doi-asserted-by":"publisher","first-page":"175","DOI":"10.2337\/dc22-S011","volume":"45","author":"American Diabetes Association Professional Practice Committee","year":"2021","unstructured":"American Diabetes Association Professional Practice Committee. 11. Chronic Kidney Disease and Risk Management: standards of Medical Care in Diabetes\u20142022. Diabetes Care. 2021;45(Supplement1):175\u2013S184. https:\/\/doi.org\/10.2337\/dc22-S011.","journal-title":"Diabetes Care"},{"issue":"5S","key":"3446_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.kint.2022.06.008","volume":"102","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group","year":"2022","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in chronic Kidney Disease. Kidney Int. 2022;102(5S):1\u2013S127. https:\/\/doi.org\/10.1016\/j.kint.2022.06.008.","journal-title":"Kidney Int"},{"issue":"9","key":"3446_CR14","doi-asserted-by":"publisher","first-page":"e023811","DOI":"10.1161\/JAHA.121.023811","volume":"11","author":"R Adhikari","year":"2022","unstructured":"Adhikari R, Jha K, Dardari Z, et al. National trends in Use of Sodium-glucose Cotransporter\u20102 inhibitors and Glucagon\u2010like Peptide\u20101 receptor agonists by cardiologists and other specialties, 2015 to 2020. J Am Heart Assoc Cardiovasc Cerebrovasc Dis. 2022;11(9):e023811. https:\/\/doi.org\/10.1161\/JAHA.121.023811.","journal-title":"J Am Heart Assoc Cardiovasc Cerebrovasc Dis"},{"issue":"12","key":"3446_CR15","doi-asserted-by":"publisher","first-page":"e008381","DOI":"10.1161\/CIRCOUTCOMES.121.008381","volume":"14","author":"V Sangha","year":"2021","unstructured":"Sangha V, Lipska K, Lin Z, et al. Patterns of prescribing sodium-glucose Cotransporter-2 inhibitors for Medicare Beneficiaries in the United States. Circ Cardiovasc Qual Outcomes. 2021;14(12):e008381. https:\/\/doi.org\/10.1161\/CIRCOUTCOMES.121.008381.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"4","key":"3446_CR16","doi-asserted-by":"publisher","first-page":"e216139","DOI":"10.1001\/jamanetworkopen.2021.6139","volume":"4","author":"LA Eberly","year":"2021","unstructured":"Eberly LA, Yang L, Eneanya ND, et al. Association of Race\/Ethnicity, gender, and socioeconomic status with sodium-glucose cotransporter 2 inhibitor use among patients with Diabetes in the US. JAMA Netw Open. 2021;4(4):e216139. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.6139.","journal-title":"JAMA Netw Open"},{"issue":"12","key":"3446_CR17","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1258\/jrsm.2011.110180","volume":"104","author":"ZS Morris","year":"2011","unstructured":"Morris ZS, Wooding S, Grant J. The answer is 17 years, what is the question: understanding time lags in translational research. J R Soc Med. 2011;104(12):510\u201320. https:\/\/doi.org\/10.1258\/jrsm.2011.110180.","journal-title":"J R Soc Med"},{"issue":"6","key":"3446_CR18","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1370\/afm.1713","volume":"12","author":"T Bodenheimer","year":"2014","unstructured":"Bodenheimer T, Sinsky C. From triple to quadruple aim: care of the patient requires care of the provider. Ann Fam Med. 2014;12(6):573\u20136. https:\/\/doi.org\/10.1370\/afm.1713.","journal-title":"Ann Fam Med"},{"issue":"1","key":"3446_CR19","doi-asserted-by":"publisher","first-page":"81","DOI":"10.18553\/jmcp.2016.22.1.81","volume":"22","author":"J Moon","year":"2016","unstructured":"Moon J, Kolar C, Brummel A, Ekstrand M, Holtan H, Rehrauer D. Development and validation of a patient satisfaction survey for Comprehensive Medication Management. J Manag Care Spec Pharm. 2016;22(1):81\u20136. https:\/\/doi.org\/10.18553\/jmcp.2016.22.1.81.","journal-title":"J Manag Care Spec Pharm"},{"issue":"4","key":"3446_CR20","doi-asserted-by":"publisher","first-page":"462","DOI":"10.3122\/jabfm.2019.04.180376","volume":"32","author":"KA Funk","year":"2019","unstructured":"Funk KA, Pestka DL, Roth McClurg MT, Carroll JK, Sorensen TD. Primary care providers believe that Comprehensive Medication Management improves their work-life. J Am Board Fam Med JABFM. 2019;32(4):462\u201373. https:\/\/doi.org\/10.3122\/jabfm.2019.04.180376.","journal-title":"J Am Board Fam Med JABFM"},{"issue":"2","key":"3446_CR21","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1331\/JAPhA.2008.07108","volume":"48","author":"BJ Isetts","year":"2008","unstructured":"Isetts BJ, Schondelmeyer SW, Artz MB, et al. Clinical and economic outcomes of medication therapy management services: the Minnesota experience. J Am Pharm Assoc JAPhA. 2008;48(2):203\u201311.","journal-title":"J Am Pharm Assoc JAPhA"},{"issue":"5","key":"3446_CR22","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1089\/pop.2017.0167","volume":"21","author":"H Budlong","year":"2018","unstructured":"Budlong H, Brummel A, Rhodes A, Nici H. Impact of Comprehensive Medication Management on Hospital Readmission Rates. Popul Health Manag. 2018;21(5):395\u2013400. https:\/\/doi.org\/10.1089\/pop.2017.0167.","journal-title":"Popul Health Manag"},{"issue":"1","key":"3446_CR23","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1089\/pop.2012.0023","volume":"16","author":"AR Brummel","year":"2013","unstructured":"Brummel AR, Soliman AM, Carlson AM, de Oliveira DR. Optimal Diabetes care outcomes following face-to-face medication therapy management services. Popul Health Manag. 2013;16(1):28\u201334. https:\/\/doi.org\/10.1089\/pop.2012.0023.","journal-title":"Popul Health Manag"},{"issue":"9","key":"3446_CR24","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1016\/j.clinthera.2014.06.030","volume":"36","author":"JD Hirsch","year":"2014","unstructured":"Hirsch JD, Steers N, Adler DS, et al. Primary care-based, pharmacist-physician collaborative medication-therapy management of Hypertension: a randomized, pragmatic trial. Clin Ther. 2014;36(9):1244\u201354. https:\/\/doi.org\/10.1016\/j.clinthera.2014.06.030.","journal-title":"Clin Ther"},{"issue":"3","key":"3446_CR25","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.japh.2021.12.015","volume":"62","author":"ML Wagner","year":"2022","unstructured":"Wagner ML, McCarthy C, Bateman MT, Simmons D, Prioli KM. Pharmacists improve Diabetes outcomes: a randomized controlled trial. J Am Pharm Assoc JAPhA. 2022;62(3):775\u2013782e3. https:\/\/doi.org\/10.1016\/j.japh.2021.12.015.","journal-title":"J Am Pharm Assoc JAPhA"},{"issue":"2","key":"3446_CR26","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1161\/CIRCULATIONAHA.115.015464","volume":"132","author":"RT Tsuyuki","year":"2015","unstructured":"Tsuyuki RT, Houle SKD, Charrois TL, et al. Randomized Trial of the Effect of Pharmacist Prescribing on improving blood pressure in the community: the Alberta Clinical Trial in optimizing Hypertension (RxACTION). Circulation. 2015;132(2):93\u2013100. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.115.015464.","journal-title":"Circulation"},{"key":"3446_CR27","unstructured":"Agency for Healthcare Research and Quality. About Learning Health Systems. Accessed August 1., 2023. https:\/\/www.ahrq.gov\/learning-health-systems\/about.html."},{"issue":"19","key":"3446_CR28","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","volume":"385","author":"LA Inker","year":"2021","unstructured":"Inker LA, Eneanya ND, Coresh J, et al. New Creatinine- and cystatin C\u2013Based equations to Estimate GFR without Race. N Engl J Med. 2021;385(19):1737\u201349. https:\/\/doi.org\/10.1056\/NEJMoa2102953.","journal-title":"N Engl J Med"},{"issue":"14","key":"3446_CR29","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1001\/jama.2017.11152","volume":"318","author":"JA Linder","year":"2017","unstructured":"Linder JA, Meeker D, Fox CR, et al. Effects of behavioral interventions on Inappropriate Antibiotic Prescribing in Primary Care 12 months after stopping interventions. JAMA. 2017;318(14):1391\u20132. https:\/\/doi.org\/10.1001\/jama.2017.11152.","journal-title":"JAMA"},{"issue":"4","key":"3446_CR30","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1370\/afm.2094","volume":"15","author":"KA Wallis","year":"2017","unstructured":"Wallis KA, Andrews A, Henderson M. Swimming against the Tide: Primary Care Physicians\u2019 views on Deprescribing in Everyday Practice. Ann Fam Med. 2017;15(4):341\u20136. https:\/\/doi.org\/10.1370\/afm.2094.","journal-title":"Ann Fam Med"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-023-03446-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-023-03446-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-023-03446-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T16:04:45Z","timestamp":1704470685000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-023-03446-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,5]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3446"],"URL":"https:\/\/doi.org\/10.1186\/s12882-023-03446-1","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,5]]},"assertion":[{"value":"1 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Minneapolis VA Health Care System Human Research Protection Program determined that, as a quality improvement initiative, this study did not meet the definition of research and, therefore, did not need institutional review board (IRB) oversight.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"14"}}